Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol (Q43601806)

25 November 2017

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A605911

15 July 2022

1 reference

D. C. Case

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A605911

15 July 2022

D. J. Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A605911

15 July 2022

B. D. Clarkson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A605911

15 July 2022

language of work or name

English

0 references

publication date

1 December 1977

1 reference

full work available at URL

25 November 2017

https://api.elsevier.com/content/article/PII:0002934377905435?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

https://api.elsevier.com/content/article/PII:0002934377905435?httpAccept=text/plain

4 August 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

American Journal of Medicine

4 August 2023

published in

1 reference

25 November 2017

63

1 reference

25 November 2017

6

1 reference

25 November 2017

897-903

1 reference

Combination chemotherapy for multiple myeloma

25 November 2017

3

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Plasma cell myeloma. An interpretive review

4 August 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Cyclophosphamide vs melphalan in treatment of plasma cell myeloma

4 August 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Clinical trials with N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride in malignant lymphoma and other disseminated neoplasia

4 August 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse

4 August 2023

11

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU

4 August 2023

16

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma

4 August 2023

17

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Kinetics of tumor growth and regression in IgG multiple myeloma

4 August 2023

18

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

4 August 2023

19

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Prognostic factors in multiple myeloma

4 August 2023

20

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Nonparametric Estimation from Incomplete Observations

4 August 2023

22

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Prognosis of Myelomatosis on Treatment with Prednisone and Cytostatics

4 August 2023

25

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Growth rates and responses to treatment in human myelomatosis

4 August 2023

26

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Immunoglobulin synthesis and tumor kinetics of multiple myeloma

4 August 2023

27

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

Effect of chemotherapy in the labelling index of myeloma cells

4 August 2023

29

1 reference

https://api.crossref.org/works/10.1016/0002-9343(77)90543-5

4 August 2023

Identifiers

1 reference

25 November 2017

1 reference